-
5 days ago | 
pharmacytimes.com | Steven Nissen |Alana Hippensteele
CommentaryArticleJune 2, 2025Author(s):,Bempedoic acid is an effective option for statin-intolerant patients or those needing additional low-density lipoprotein cholesterol (LDL-C) reduction, with clinical trials showing cardiovascular benefits, key drug-drug interaction considerations, and special management factors in patients with comorbidities.
-
6 days ago | 
pharmacytimes.com | Alana Hippensteele
As the evidence base for lipid management continues to grow, understanding the timing, intensity, and duration of therapy has become crucial for optimizing patient outcomes. At the 2025 National Lipid Association (NLA) Scientific Sessions, Kausik K. Ray, MD, FMedSci, discussed the importance of early, sustained, and aggressive low-density lipoprotein cholesterol (LDL-C) lowering for atherosclerotic cardiovascular disease (ASCVD) prevention.
-
6 days ago | 
pharmacytimes.com | Alana Hippensteele
The role of remnant cholesterol and triglyceride-rich lipoproteins (TRLs) in atherosclerotic cardiovascular disease (ASCVD) has garnered increasing attention in recent years, reshaping how clinicians and researchers approach lipid management. At the 2025 National Lipid Association (NLA) Scientific Sessions, Børge G. Nordestgaard, MD, DMSc, discussed the evolving understanding of remnant cholesterol, TRLs, and their roles in ASCVD.
-
6 days ago | 
pharmacytimes.com | Alana Hippensteele
CommentaryArticleJune 1, 2025Author(s):Incretin-based therapies, including GLP-1 and dual GLP-1/GIP receptor agonists, are transforming the management of type 2 diabetes, obesity, and cardiovascular risk. The use of incretin-based therapies has rapidly expanded in recent years, driven by advances in understanding their mechanisms, efficacy across multiple metabolic outcomes, and broadening indications.
-
1 week ago | 
pharmacytimes.com | Frank Qian |Alana Hippensteele
CommentaryVideoJune 1, 2025Author(s):,Frank Qian, MD, MPH, discusses clinical considerations for omega-3 fatty acid therapy, such as the patient populations who may benefit most and important safety concerns. As interest in omega-3 fatty acids continues to grow, so do questions about their clinical applications, safety, and efficacy.
-
1 week ago | 
pharmacytimes.com | Frank Qian |Alana Hippensteele
CommentaryVideoMay 31, 2025Author(s):,Frank Qian, MD, MPH, discusses the clinical indications, dosing strategies, and cardiovascular outcomes data for prescription omega-3 fatty acids, including the ongoing debate about EPA vs EPA-DHA formulations and the implications of recent trial findings. Omega-3 fatty acids have long been recognized for their role in lipid management, but their clinical applications, particularly for cardiovascular risk reduction, continue to evolve.
-
1 week ago | 
pharmacytimes.com | Alana Hippensteele
Glucagon-like peptide-1 (GLP-1) receptor agonists have emerged as a cornerstone of obesity pharmacotherapy, with data demonstrating multifaceted benefits that extend beyond weight loss alone. At the 2025 National Lipid Association (NLA) Scientific Sessions, Samuel Klein, MD, a professor of medicine and nutritional science at Washington University School of Medicine in St. Louis, discussed the transformative impact of GLP-1 receptor agonists on obesity management and cardiometabolic health.
-
1 week ago | 
pharmacytimes.com | Alana Hippensteele
As the understanding of cardiovascular risk continues to evolve, the focus on lipoprotein(a) (Lp[a]) as an independent and causal risk factor for atherosclerotic disease has grown. At the 2025 National Lipid Association (NLA) Scientific Sessions, Marlys L. Koschinsky, PhD, FNLA, discussed the evolving landscape of Lp(a)-targeted therapies.
-
1 week ago | 
pharmacytimes.com | Alana Hippensteele
In the field of lipidology, emerging therapies targeting apolipoprotein C-III (ApoC3) are altering the management of hypertriglyceridemia and associated cardiovascular risks, according to Daniel Gaudet, MD, PhD, a professor of medicine at the Université de Montréal in Canada.
-
1 week ago | 
pharmacytimes.com | Sander Kersten |Alana Hippensteele
CommentaryArticleMay 30, 2025Author(s):,Sander Kersten, PhD, discusses the distinct roles of ANGPTL3 and ANGPTL4 in lipid metabolism, their interactions with key enzymes, the therapeutic potential of targeting these pathways in lipid-lowering strategies, and important considerations for pharmacists counseling patients on emerging ANGPTL-targeted therapies.
